Revelation Biosciences, Inc.(REVB)Earnings, Financials & Key Ratios

REVB•NASDAQ

$0.98

Price updated Jun 27, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryVaccines and Infectious Disease

AboutRevelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.Show more

Revenue$0
EBITDA-$9M-13.8%
Net Income-$9M+40.7%
EPS (Diluted)-23.95+72.7%
ROE-131.38%+50.4%

REVB Price & Volume

Revelation Biosciences, Inc. (REVB) stock price & volume — 10-year historical chart

Loading chart...

Clinical Development Costs Drive Persistent Equity Dilution

Investment Thesis • Updated 2026Q1

VerdictNegative

Growth:Contracting

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Binary clinical trial failure

Key Thesis Takeaways

Revelation Biosciences remains a pre-commercial clinical-stage entity characterized by a high-burn operational model that necessitates frequent reliance on external capital.
The company's lack of consistent revenue, evidenced by the $3.1 million operating loss in 2026Q1, underscores the binary risk profile inherent in its therapeutic pipeline.
Investors should monitor the rapid depletion of cash reserves, which fell to $10.7 million in 2025Q4, as this trajectory suggests a high probability of future dilutive financing events to sustain ongoing research and development.

Verdict Logic

the company's reliance on equity-linked financing to cover a $3.3 million quarterly free cash flow burn creates a significant dilution overhang for shareholders.

REVB Growth Metrics

Revelation Biosciences, Inc. (REVB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-100%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM31.49%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM87.19%

Return on Capital

10 Years-935.37%

5 Years-994.11%

3 Years-164.07%

Last Year-126.93%

Peers Comparison

Key metrics vs top competitors for Revelation Biosciences, Inc. (REVB)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
REVBRevelation Biosciences, Inc.Current	$0.98	$3.14M	-0.04	—	—	-131.38%	—
ADMAADMA Biologics, Inc.	$8.75	$2.03B	14.58	19.63%	32.43%	38.97%	—
AGENAgenus Inc.	$3.03	$126.18M	-891.18	10.37%	52.16%	—	—
IMVTImmunovant, Inc.	$38.85	$7.98B	-14.03	—	—	-68.16%	—
HALOHalozyme Therapeutics, Inc.	$74.96	$8.89B	29.28	37.55%	23.13%	126.27%	—
NVAXNovavax, Inc.	$8.88	$1.46B	3.50	64.69%	-14.73%	—	—